The Management Board of Pharmena S.A. forwards the monthly report for July 2017 br> 1. Description of trends and events in the Issuer's environment br> According to the Management Board, in July 2017, the Issuer did not have any phenomena or trends that could have a significant impact on the company's financial results. br> During this period, Pharmena S.A. broadened the availability of products and undertook marketing activities to increase the revenue from the sale of products offered. In addition, in July 2017, the Issuer's Capital Group continued its research and development work on new products and the search for new applications of active substances protected by patents and patent applications belonging to the Issuer's Capital Group. Year> 2. Realization of emission goals br> In connection with the completion of the second phase of clinical trials on the innovative drug 1-MNA and the settlement of expenses in July 2017, both Pharmena S.A. and the subsidiary Cortria Corporation did not spend cash for issue purposes. Br> 3. List of reports published by the Issuer in the period from 01/07/2017 to 31/07/2017. Br> During the period covered by this report, Pharmena S.A. published the following reports in the EBI system: br> • Current report No. 22/2017 of 12-07-2017 - Monthly report for June 2017 br> During the period covered by this report, Pharmena S.A. did not publish reports in the ESPI system. br> 4. Investor's calendar regarding August 2017 br> 11/08/2017 - publication of a separate and consolidated report for the second quarter of 2017 br> Until 14/09/2017 - publication of the monthly report for August 2017 br > Legal basis: point 16 of Annex No. 1 to Resolution No. 795/2008 of the Exchange Management Board of November 31, 2008 - "Best Practices of Companies Listed on NewConnect". Br>
Automatic translation of the announcements.